

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

IMMUNOMEDICS INC
Form 8-K
October 13, 2004

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): October 7, 2004

Immunomedics, Inc.

(Exact Name of Registrant as Specified in Its Charter)

Delaware

000-12104

61-1009366

(State or Other Jurisdiction
of Incorporation)

(Commission
File Number)

(I.R.S. Employer
Identification No.)

300 American Road, Morris Plains, New Jersey

07950

(Address of Principal Executive Offices)

(Zip Code)

Registrant's telephone number, including area code:

(973) 605-8200

Not Applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 5.02. Departure of Directors or Principal Officers; Election of Directors; Appointment of Principal Officers.

Edgar Filing: IMMUNOMEDICS INC - Form 8-K

(d) On October 12, 2004, Immunomedics, Inc. (the "Company") issued a press release announcing that Brian A. Markison has been appointed to the Company's Board of Directors. Mr. Markison was appointed by the Board of Directors on October 7, 2004, and was named as a member of the Company's Governance and Nominating Committee and Research and Development Committee. Mr. Markison will stand for election together with the Company's other directors at the Company's 2004 annual meeting of stockholders. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(c) Exhibits:

99.1 Press Release, dated October 12, 2004

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: October 13, 2004

IMMUNOMEDICS, INC.

By: /s/ Gerard G. Gorman

Name: Gerard G. Gorman
Title: Vice President, Finance, and
Chief Financial Officer

EXHIBIT INDEX

EXHIBIT NUMBER

DESCRIPTION

99.1

Press Release, dated October 12, 2004